The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Prophylactic Oophorectomy in Carriers of BRCA1 or BRCA2 Mutations
Abstract
BACKGROUND: Data concerning the efficacy of bilateral prophylactic oophorectomy for reducing the risk of gynecologic cancer in women with BRCA1 or BRCA2 mutations are limited. We investigated whether this procedure reduces the risk of cancers of the coelomic epithelium and breast in women who carry such mutations. METHODS: A total of 551 women with disease-associated germ-line BRCA1 or BRCA2 mutations were identified from registries and studied for the occurrence of ovarian and breast cancer. We determined the incidence of ovarian cancer in 259 women who had undergone bilateral prophylactic oophorectomy and in 292 matched controls who had not undergone the procedure. In a subgroup of 241 women with no history of breast cancer or prophylactic mastectomy, the incidence of breast cancer was determined in 99 women who had undergone bilateral prophylactic oophorectomy and in 142 matched controls. The length of postoperative follow-up for both groups was at least eight years. RESULTS: Six women who underwent prophylactic oophorectomy (2.3 percent) received a diagnosis of stage I ovarian cancer at the time of the procedure; two women (0.8 percent) received a diagnosis of papillary serous peritoneal carcinoma 3.8 and 8.6 years after bilateral prophylactic oophorectomy. Among the controls, 58 women (19.9 percent) received a diagnosis of ovarian cancer, after a mean follow-up of 8.8 years. With the exclusion of the six women whose cancer was diagnosed at surgery, prophylactic oophorectomy significantly reduced the risk of coelomic epithelial cancer (hazard ratio, 0.04; 95 percent confidence interval, 0.01 to 0.16). Of 99 women who underwent bilateral prophylactic oophorectomy and who were studied to determine the risk of breast cancer, breast cancer developed in 21 (21.2 percent), as compared with 60 (42.3 percent) in the control group (hazard ratio, 0.47; 95 percent confidence interval, 0.29 to 0.77). CONCLUSIONS: Bilateral prophylactic oophorectomy reduces the risk of coelomic epithelial cancer and breast cancer in women with BRCA1 or BRCA2 mutations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genetic Heterogeneity and Penetrance Analysis of the BRCA1 and BRCA2 Genes in Breast Cancer Families
Ford, D., Easton, D. F., Stratton, M., Narod, S., Goldgar, D., Devilee, P., Bishop, D. T., Weber, B., Lenoir, G., Chang-Claude, J., et al. (1998) · The American Journal of Human Genetics · doi:10.1086/301749 · Cited by 3,037
Self-citationThe Robust Inference for the Cox Proportional Hazards Model
Lin, D. Y., & Wei, L. J. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478874 · Cited by 2,695
The Risk of Cancer Associated with Specific Mutations of BRCA1 and BRCA2 among Ashkenazi Jews
Struewing, J. P., Hartge, P., Wacholder, S., Baker, S. M., Berlin, M., McAdams, M., Timmerman, M. M., Brody, L. C., & Tucker, M. A. (1997) · New England Journal of Medicine · doi:10.1056/nejm199705153362001 · Cited by 2,281
Menopause and the Risk of Coronary Heart Disease in Women
Colditz, G. A., Willett, W. C., Stampfer, M. J., Rosner, B., Speizer, F. E., & Hennekens, C. H. (1987) · New England Journal of Medicine · doi:10.1056/nejm198704303161801 · Cited by 1,148
Burke, W. (1997) · JAMA · doi:10.1001/jama.277.12.997 · Cited by 955
Breast Cancer Risk After Bilateral Prophylactic Oophorectomy in BRCA1 Mutation Carriers
Rebbeck, T. R., Levin, A. M., Eisen, A., Snyder, C., Watson, P., Cannon-Albright, L., Isaacs, C., Olopade, O., Garber, J. E., Godwin, A. K., et al. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.17.1475 · Cited by 672
Self-citationOral Contraceptives and the Risk of Hereditary Ovarian Cancer
Narod, S. A., Risch, H., Moslehi, R., Dørum, A., Neuhausen, S., Olsson, H., Provencher, D., Radice, P., Evans, G., Bishop, S., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808133390702 · Cited by 615
Self-citationModan, B., Hartge, P., Hirsh-Yechezkel, G., Chetrit, A., Lubin, F., Beller, U., Ben-Baruch, G., Fishman, A., Menczer, J., Struewing, J. P., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107263450401 · Cited by 385
Piver, M. S., Jishi, M. F., Tsukada, Y., & Nava, G. (1993) · Cancer · doi:10.1002/1097-0142(19930501)71:9<2751::aid-cncr2820710911>3.0.co;2-j · Cited by 321
Menstrual Factors and Risk of Breast Cancer
Brinton, L. A., Schairer, C., Hoover, R. N., & Fraumeni, J. F. (1988) · Cancer Investigation · doi:10.3109/07357908809080645 · Cited by 249
Cited by
Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2
King, M.-C., Marks, J. H., & Mandell, J. B. (2003) · Science · doi:10.1126/science.1088759 · Cited by 2,229
Cannistra, S. A. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041842 · Cited by 2,129
Kriege, M., Brekelmans, C. T. M., Boetes, C., Besnard, P. E., Zonderland, H. M., Obdeijn, I. M., Manoliu, R. A., Kok, T., Peterse, H., Tilanus-Linthorst, M. M. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031759 · Cited by 1,687
Domchek, S. M. (2010) · JAMA · doi:10.1001/jama.2010.1237 · Cited by 1,494
kConFab, Lim, E., Vaillant, F., Wu, D., Forrest, N. C., Pal, B., Hart, A. H., Asselin-Labat, M.-L., Gyorki, D. E., Ward, T., et al. (2009) · Nature Medicine · doi:10.1038/nm.2000 · Cited by 1,492
The ErbB/HER family of protein-tyrosine kinases and cancer
Roskoski, R. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2013.11.002 · Cited by 1,353
Rebbeck, T. R., Friebel, T., Lynch, H. T., Neuhausen, S. L., van ’t Veer, L., Garber, J. E., Evans, G. R., Narod, S. A., Isaacs, C., Matloff, E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.188 · Cited by 1,171
“This effect is also seen in the 50% breast cancer risk reduction we reported in association with bilateral prophylactic oophorectomy [7,17].”
BackgroundSelf-citationGoldhirsch, A., Glick, J. H., Gelber, R. D., Coates, A. S., Thürlimann, B., & Senn, H.-J. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi326 · Cited by 1,127
Daly, M. B., Pal, T., Berry, M. P., Buys, S. S., Dickson, P., Domchek, S. M., Elkhanany, A., Friedman, S., Goggins, M., Hutton, M. L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0001 · Cited by 1,112
Self-citationLedermann, J. A., Raja, F. A., Fotopoulou, C., Gonzalez-Martin, A., Colombo, N., & Sessa, C. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt333 · Cited by 1,104
BRCA1 and BRCA2: 1994 and beyond
Narod, S. A., & Foulkes, W. D. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1431 · Cited by 967
Self-citationSelective Estrogen-Receptor Modulators — Mechanisms of Action and Application to Clinical Practice
Riggs, B. L., & Hartmann, L. C. (2003) · New England Journal of Medicine · doi:10.1056/nejmra022219 · Cited by 968
Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE
Mavaddat, N., Peock, S., Frost, D., Ellis, S., Platte, R., Fineberg, E., Evans, D. G., Izatt, L., Eeles, R. A., Adlard, J., et al. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt095 · Cited by 951
Self-citationRebbeck, T. R., Kauff, N. D., & Domchek, S. M. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn442 · Cited by 939
Self-citationHenry, N. L., & Hayes, D. F. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.01.010 · Cited by 849
Molyneux, G., Geyer, F. C., Magnay, F.-A., McCarthy, A., Kendrick, H., Natrajan, R., MacKay, A., Grigoriadis, A., Tutt, A., Ashworth, A., et al. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.07.010 · Cited by 794
Prophylactic Surgery to Reduce the Risk of Gynecologic Cancers in the Lynch Syndrome
Schmeler, K. M., Lynch, H. T., Chen, L.-M., Munsell, M. F., Soliman, P. T., Clark, M. B., Daniels, M. S., White, K. G., Boyd-Rogers, S. G., Conrad, P. G., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052627 · Cited by 794
Self-citationHigh grade serous ovarian carcinomas originate in the fallopian tube
Labidi-Galy, S. I., Papp, E., Hallberg, D., Niknafs, N., Adleff, V., Noe, M., Bhattacharya, R., Novak, M., Jones, S., Phallen, J., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00962-1 · Cited by 759
Goldhirsch, A., Wood, W. C., Gelber, R. D., Coates, A. S., Thürlimann, B., & Senn, H.-J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.576 · Cited by 697
Hereditary Cancer Predisposition Syndromes
Garber, J. E., & Offit, K. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.042 · Cited by 697
Self-citationSpectrum of Mutations in BRCA1, BRCA2, CHEK2, and TP53 in Families at High Risk of Breast Cancer
Walsh, T., Casadei, S., Coats, K. H., Swisher, E., Stray, S. M., Higgins, J., Roach, K. C., Mandell, J., Lee, M. K., Ciernikova, S., et al. (2006) · JAMA · doi:10.1001/jama.295.12.1379 · Cited by 666
Genetic/Familial High-Risk Assessment: Breast and Ovarian
Daly, M. B., Axilbund, J. E., Buys, S., Crawford, B., Farrell, C. D., Friedman, S., Garber, J. E., Goorha, S., Gruber, S. B., Hampel, H., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0043 · Cited by 646
Self-citationHennessy, B. T., Coleman, R. L., & Markman, M. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61338-6 · Cited by 640
Cancer vaccines: between the idea and the reality
Finn, O. J. (2003) · Nature Reviews Immunology · doi:10.1038/nri1150 · Cited by 636
Contralateral Breast Cancer in BRCA1 and BRCA2 Mutation Carriers
Metcalfe, K., Lynch, H. T., Ghadirian, P., Tung, N., Olivotto, I., Warner, E., Olopade, O. I., Eisen, A., Weber, B., McLennan, J., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.033 · Cited by 621
Self-citationWooster, R., & Weber, B. L. (2003) · New England Journal of Medicine · doi:10.1056/nejmra012284 · Cited by 605
Self-citationKauff, N. D., Domchek, S. M., Friebel, T. M., Robson, M. E., Lee, J., Garber, J. E., Isaacs, C., Evans, D. G., Lynch, H., Eeles, R. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9626 · Cited by 589
Self-citationGenetics of breast cancer: a topic in evolution
Shiovitz, S., & Korde, L. A. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv022 · Cited by 525
Fertility preservation in female patients
Sonmezer, M. (2004) · Human Reproduction Update · doi:10.1093/humupd/dmh021 · Cited by 496
Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations
Fackenthal, J. D., & Olopade, O. I. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2054 · Cited by 488
Self-citationCallahan, M. J., Crum, C. P., Medeiros, F., Kindelberger, D. W., Elvin, J. A., Garber, J. E., Feltmate, C. M., Berkowitz, R. S., & Muto, M. G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2622 · Cited by 485
Self-citationThe Fanconi Anemia/BRCA pathway: new faces in the crowd
Kennedy, R. D., & D'Andrea, A. D. (2005) · Genes & Development · doi:10.1101/gad.1370505 · Cited by 467
US Preventive Services Task Force, Owens, D. K., Davidson, K. W., Krist, A. H., Barry, M. J., Cabana, M., Caughey, A. B., Doubeni, C. A., Epling, J. W., Kubik, M., et al. (2019) · JAMA · doi:10.1001/jama.2019.10987 · Cited by 467
Early Events in the Pathogenesis of Epithelial Ovarian Cancer
Landen, C. N., Birrer, M. J., & Sood, A. K. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9970 · Cited by 462
Progress and Challenges in Screening for Early Detection of Ovarian Cancer
Jacobs, I. J., & Menon, U. (2004) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r400006-mcp200 · Cited by 458
Eisen, A., Lubinski, J., Klijn, J., Moller, P., Lynch, H. T., Offit, K., Weber, B., Rebbeck, T., Neuhausen, S. L., Ghadirian, P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.7138 · Cited by 443
Self-citationRebbeck, T. R., Friebel, T., Wagner, T., Lynch, H. T., Garber, J. E., Daly, M. B., Isaacs, C., Olopade, O. I., Neuhausen, S. L., van ′t Veer, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.8151 · Cited by 411
Self-citationFinch, A., Shaw, P., Rosen, B., Murphy, J., Narod, S. A., & Colgan, T. J. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.06.065 · Cited by 375
Self-citationGenetic susceptibility to breast cancer
Mavaddat, N., Antoniou, A. C., Easton, D. F., & Garcia-Closas, M. (2010) · Molecular Oncology · doi:10.1016/j.molonc.2010.04.011 · Cited by 375
Powell, C. B., Kenley, E., Chen, L.-M., Crawford, B., McLennan, J., Zaloudek, C., Komaromy, M., Beattie, M., & Ziegler, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.109 · Cited by 372
Hall, M. J., Reid, J. E., Burbidge, L. A., Pruss, D., Deffenbaugh, A. M., Frye, C., Wenstrup, R. J., Ward, B. E., Scholl, T. A., & Noll, W. W. (2009) · Cancer · doi:10.1002/cncr.24200 · Cited by 365
Oestrogen exposure and breast cancer risk
Travis, R. C., & Key, T. J. (2003) · Breast Cancer Research · doi:10.1186/bcr628 · Cited by 346
Manahan, E. R., Kuerer, H. M., Sebastian, M., Hughes, K. S., Boughey, J. C., Euhus, D. M., Boolbol, S. K., & Taylor, W. A. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07549-8 · Cited by 346
Pierce, L. J., Levin, A. M., Rebbeck, T. R., Ben-David, M. A., Friedman, E., Solin, L. J., Harris, E. E., Gaffney, D. K., Haffty, B. G., Dawson, L. A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.7888 · Cited by 340
Self-citationLessons from BRCA: the Tubal Fimbria Emerges as an Origin for Pelvic Serous Cancer
Crum, C. P., Drapkin, R., Kindelberger, D., Medeiros, F., Miron, A., & Lee, Y. (2007) · Clinical Medicine & Research · doi:10.3121/cmr.2007.702 · Cited by 342
Two Decades After BRCA: Setting Paradigms in Personalized Cancer Care and Prevention
Couch, F. J., Nathanson, K. L., & Offit, K. (2014) · Science · doi:10.1126/science.1251827 · Cited by 342
Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2
Petrucelli, N., Daly, M. B., & Feldman, G. L. (2010) · Genetics in Medicine · doi:10.1097/gim.0b013e3181d38f2f · Cited by 339
Self-citationDomchek, S. M., Friebel, T. M., Neuhausen, S. L., Wagner, T., Evans, G., Isaacs, C., Garber, J. E., Daly, M. B., Eeles, R., Matloff, E., et al. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70585-x · Cited by 327
Self-citationCharacterization of BRCA1 and BRCA2 Mutations in a Large United States Sample
Chen, S., Iversen, E. S., Friebel, T., Finkelstein, D., Weber, B. L., Eisen, A., Peterson, L. E., Schildkraut, J. M., Isaacs, C., Peshkin, B. N., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.6772 · Cited by 317
Self-citationMutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations
Rebbeck, T. R., Friebel, T. M., Friedman, E., Hamann, U., Huo, D., Kwong, A., Olah, E., Olopade, O. I., Solano, A. R., Teo, S.-H., et al. (2018) · Human Mutation · doi:10.1002/humu.23406 · Cited by 312
Self-citationEpithelial Ovarian Cancer: A Review of Current Management
Guppy, A. E., Nathan, P. D., & Rustin, G. J. S. (2005) · Clinical Oncology · doi:10.1016/j.clon.2005.05.009 · Cited by 311
RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers
Nolan, E., Vaillant, F., Branstetter, D., Pal, B., Giner, G., Whitehead, L., Lok, S. W., Mann, G. B., Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Rohrbach, K., et al. (2016) · Nature Medicine · doi:10.1038/nm.4118 · Cited by 309
Primary and metastatic peritoneal surface malignancies
Cortés-Guiral, D., Hübner, M., Alyami, M., Bhatt, A., Ceelen, W., Glehen, O., Lordick, F., Ramsay, R., Sgarbura, O., Van Der Speeten, K., et al. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00326-6 · Cited by 308
Models of genetic susceptibility to breast cancer
Antoniou, A. C., & Easton, D. F. (2006) · Oncogene · doi:10.1038/sj.onc.1209879 · Cited by 303
Focus on epithelial ovarian cancer
Ozols, R. F., Bookman, M. A., Connolly, D. C., Daly, M. B., Godwin, A. K., Schilder, R. J., Xu, X., & Hamilton, T. C. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00002-9 · Cited by 294
Self-citationSteroid Hormone Receptor Status of Mouse Mammary Stem Cells
Asselin-Labat, M.-L., Shackleton, M., Stingl, J., Vaillant, F., Forrest, N. C., Eaves, C. J., Visvader, J. E., & Lindeman, G. J. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj267 · Cited by 293
van Sprundel, T. C., Schmidt, M. K., Rookus, M. A., Brohet, R., van Asperen, C. J., Rutgers, E. J. T., van‘t Veer, L. J., & Tollenaar, R. A. E. M. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602703 · Cited by 291
Self-citationCancer Suppression by the Chromosome Custodians, BRCA1 and BRCA2
Venkitaraman, A. R. (2014) · Science · doi:10.1126/science.1252230 · Cited by 289
Tubal ligation and the risk of ovarian cancer: review and meta-analysis
Cibula, D., Widschwendter, M., Majek, O., & Dusek, L. (2011) · Human Reproduction Update · doi:10.1093/humupd/dmq030 · Cited by 283
Antoniou, A. C., Spurdle, A. B., Sinilnikova, O. M., Healey, S., Pooley, K. A., Schmutzler, R. K., Versmold, B., Engel, C., Meindl, A., Arnold, N., et al. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.02.008 · Cited by 283
Self-citationCell Origins of High-Grade Serous Ovarian Cancer
Kim, J., Park, E., Kim, O., Schilder, J., Coffey, D., Cho, C.-H., & Bast, R. (2018) · Cancers · doi:10.3390/cancers10110433 · Cited by 264
Cost-effectiveness of Screening BRCA1/2 Mutation Carriers With Breast Magnetic Resonance Imaging
Plevritis, S. K., Kurian, A. W., Sigal, B. M., Daniel, B. L., Ikeda, D. M., Stockdale, F. E., & Garber, A. M. (2006) · JAMA · doi:10.1001/jama.295.20.2374 · Cited by 260
Thewes, B., Meiser, B., Taylor, A., Phillips, K. A., Pendlebury, S., Capp, A., Dalley, D., Goldstein, D., Baber, R., & Friedlander, M. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.773 · Cited by 256
Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update
Gronwald, J., Tung, N., Foulkes, W. D., Offit, K., Gershoni, R., Daly, M., Kim‐Sing, C., Olsson, H., Ainsworth, P., Eisen, A., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.21536 · Cited by 254
Self-citationThe Role of Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer
Hartmann, L. C., & Lindor, N. M. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1503523 · Cited by 253
Management of an Inherited Predisposition to Breast Cancer
Robson, M., & Offit, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmcp071286 · Cited by 252
Mechanisms of BRCA1 Tumor Suppression
Silver, D. P., & Livingston, D. M. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0221 · Cited by 159
“Notable in this regard are results showing that breast cancer development in BRCA1-affected women is an estrogen-dependent process (49, 50).”
Kirova, Y. M., Stoppa-Lyonnet, D., Savignoni, A., Sigal-Zafrani, B., Fabre, N., & Fourquet, A. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.02.037 · Cited by 129
BRCA1 Deficiency Exacerbates Estrogen-Induced DNA Damage and Genomic Instability
Savage, K. I., Matchett, K. B., Barros, E. M., Cooper, K. M., Irwin, G. W., Gorski, J. J., Orr, K. S., Vohhodina, J., Kavanagh, J. N., Madden, A. F., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2611 · Cited by 124
“carriers significantly reduces the risk of breast cancer onset and recurrence (6-8).”
BackgroundBreast-Conserving Surgery in BRCA1/2 Mutation Carriers: Are We Approaching an Answer?
Garcia-Etienne, C. A., Barile, M., Gentilini, O. D., Botteri, E., Rotmensz, N., Sagona, A., Farante, G., Galimberti, V., Luini, A., Veronesi, P., et al. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0638-7 · Cited by 100
Genome Sequencing during a Patient’s Journey through Cancer
Nangalia, J., & Campbell, P. J. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1910138 · Cited by 66
Surgical risk reduction: Prophylactic salpingo-oophorectomy and prophylactic mastectomy
Dowdy, S. C., Stefanek, M., & Hartmann, L. C. (2004) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.04.028 · Cited by 61
Impact of risk-reducing salpingo-oophorectomy in premenopausal women
Vermeulen, R. F. M., Beurden, M. V., Korse, C. M., & Kenter, G. G. (2017) · Climacteric · doi:10.1080/13697137.2017.1285879 · Cited by 62
Risk‐Reduction Surgery Decisions in High‐Risk Women Seen for Genetic Counseling
Ray, J. A., Loescher, L. J., & Brewer, M. (2005) · Journal of Genetic Counseling · doi:10.1007/s10897-005-5833-5 · Cited by 53
Lee, J. M., Kopans, D. B., McMahon, P. M., Halpern, E. F., Ryan, P. D., Weinstein, M. C., & Gazelle, G. S. (2008) · Radiology · doi:10.1148/radiol.2463070224 · Cited by 45
van Driel, C., de Bock, G., Schroevers, M., & Mourits, M. (2019) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.15471 · Cited by 33
Liu, T., Yu, J., Gao, Y., Ma, X., Jiang, S., Gu, Y., & Ming, W.-K. (2023) · Cancers · doi:10.3390/cancers16010103 · Cited by 21
AlHilli, M. M., & Al-Hilli, Z. (2019) · Journal of Minimally Invasive Gynecology · doi:10.1016/j.jmig.2018.09.767 · Cited by 15
Plusquin, C., Fastrez, M., Vandromme, J., & Rozenberg, S. (2011) · Maturitas · doi:10.1016/j.maturitas.2011.09.007 · Cited by 10
Precision Prevention: The Current State and Future of Genomically Guided Cancer Prevention
Kassem, N., Stout, L. A., Hunter, C., Schneider, B., & Radovich, M. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00278 · Cited by 5
Metadata
- Authors
- Rebbeck, T. R., Lynch, H. T., Neuhausen, S. L., Narod, S. A., van't Veer, L., Garber, J. E., Evans, G., Isaacs, C., Daly, M. B., Matloff, E., Olopade, O. I., & Weber, B. L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-05-23
- Volume
- 346
- Issue
- 21
- Pages
- 1616-1622
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2038793520
- Cited by
- 1,465
- References
- 16
- FWCI
- 54.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.